Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
01 December 2022 - 11:00PM
Business Wire
- Recognition Marks Alnylam’s Eighth Year in a
Row on this Prestigious List, and the Second Consecutive Year
Ranking #1 -
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced its first-place ranking in Boston
Globe’s 2022 Top Places to Work in the “Largest Employer” category.
This marks the second year in a row Alnylam’s takes the top spot in
the Largest Employer category (> 1,000 employees).
“I’m immensely proud of our team as we reach our eighth
consecutive year on Boston Globe’s Top Places to Work,” said Yvonne
Greenstreet, MBChB, Chief Executive Officer of Alnylam. “To be
ranked first on the list two years running is a testament to our
commitment to excellence. When you build an atmosphere that’s
diverse, equitable, inclusive, and full of high-performing,
challenge-hungry people looking to change the world, good things
happen.”
Companies named to the Top Places to Work list are chosen by the
people who best understand the workplace environment: the
employees. Employees complete an anonymous, research-backed survey
assessing categories including their company’s direction,
execution, connection, management, work, pay and benefits. The list
spotlights companies that support employees both in and out of the
office, including caregiving, mental health, and other
out-of-office needs.
The Top Places to Work survey is completed by 90,000 employees,
across 381 different companies in Massachusetts. The winners share
key traits, including offering more flexibility to continue working
remotely, tracking progress on efforts to support a diverse
workforce, and, above all, remembering to have some fun along the
way. This honor comes shortly after Alnylam’s second-place ranking
on Science Magazine’s 2022 Top Employer Survey.
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has
led the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of people afflicted with rare and prevalent diseases with
unmet need. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach yielding
transformative medicines. Since its founding 20 years ago, Alnylam
has led the RNAi Revolution and continues to deliver on a bold
vision to turn scientific possibility into reality. Alnylam’s
commercial RNAi therapeutic products are ONPATTRO® (patisiran),
GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran)
and Leqvio® (inclisiran) being developed and commercialized by
Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam, on LinkedIn, or on
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201005179/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom (Investors and Media)
+1-617-682-4340
Josh Brodsky (Investors) +1-617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024